AARTIDRUGSAarti Drugs

₹503.6+0.03%

Market Cap

₹4,595.44 Cr

Stock P/E

24.34

ROCE

13.11%

ROE

12.68%

Book Value

₹155.91

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Revenue growth and gross margin expansion indicate improving profitability.
•
EBITDA growth reflects operating leverage, with margins expanding to a healthier level.

NEGATIVES

•
Current EBITDA under-absorption of gross margins due to sub-optimal capacity utilization.
•
Salicylic acid plant remains a near-term drag as losses are expensed during startup and ramp-up risks persist.

Peers Summary

Sector Leader

Aarti Drugs Ltd. shows a mixed performance in comparison to its peers in the Pharmaceuticals & Drugs sector. While it exhibits lower revenue growth and profitability metrics compared to several competitors, its debt levels are manageable, suggesting a stable positioning. Companies like Cipla and Dr. Reddy's lead in profitability, while Aarti presents a value opportunity with its relatively lower valuation metrics.

Key Points

• Aarti Drugs has a manageable debt-equity ratio of 0.4389, indicating lower financial risk.
• Its revenue growth has been negative YoY at -5.6%, suggesting current operational challenges.
• Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit significantly higher profitability with ROE above 16% and PE ratios suggesting overvaluation in the market.

Top Performers

Cipla Ltd.

Highest profitability with significant revenue growth and low PE ratio.

Dr. Reddy's Laboratories Ltd.

Strong profitability metrics with a low PE ratio and high return on equity.

Mankind Pharma Ltd.

Impressive revenue growth and strong margins, although relatively higher PE.

Explore

Watchlists

Command Palette